Clinical Trial Update: A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AGN-190584 topical eyedrops for presbyopia and its impact on night-driving performance. The study has completed and results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• AGN-190584

Snippet

Sponsor: AbbVie | Conditions: Presbyopia | Phase 3 | Status: COMPLETED | Results posted: 2024-10-10